CPRX Key Statistics, Chart & Performance
The current stock price of CPRX is 23.62 USD. In the past month the price increased by 2.61%. In the past year, price increased by 10.48%.
CPRX Latest News, Press Relases and Analysis
CPRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.63 | 394.69B | ||
| AMGN | AMGEN INC | 14.53 | 171.10B | ||
| GILD | GILEAD SCIENCES INC | 14.7 | 149.38B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 77.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.51 | 52.52B | ||
| INSM | INSMED INC | N/A | 42.02B | ||
| NTRA | NATERA INC | N/A | 32.01B | ||
| BIIB | BIOGEN INC | 10.4 | 25.54B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.72 | 21.27B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.26B | ||
| INCY | INCYTE CORP | 14.86 | 18.73B |
Related stock screener links
About CPRX
Company Profile
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company is headquartered in Coral Gables, Florida and currently employs 181 full-time employees. The company went IPO on 2006-11-08. The firm markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
Company Info
CATALYST PHARMACEUTICALS INC
355 Alhambra Circle, Suite 801
Coral Gables FLORIDA 33134 US
CEO: Patrick J. McEnany
Employees: 181
Phone: 13055292522
CATALYST PHARMACEUTICALS INC / CPRX FAQ
What does CATALYST PHARMACEUTICALS INC do?
Catalyst Pharmaceuticals, Inc. is a commercial-stage, patient-centric biopharmaceutical company, which focuses on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult to treat diseases. The company is headquartered in Coral Gables, Florida and currently employs 181 full-time employees. The company went IPO on 2006-11-08. The firm markets three drug products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone). FIRDAPSE is a treatment for people six years of age or older living with Lambert-Eaton myasthenic syndrome (LEMS). The Company, through its sub-licensee, also offers FIRDAPSE in Canada and Japan. FYCOMPA is a prescription medicine used alone or with other medicines to treat partial-onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. AGAMREE is a corticosteroid with a structure that retains the potent anti-inflammatory effects of traditional corticosteroids used in Duchenne muscular dystrophy.
What is the stock price of CATALYST PHARMACEUTICALS INC today?
The current stock price of CPRX is 23.62 USD. The price increased by 2.96% in the last trading session.
What is the dividend status of CATALYST PHARMACEUTICALS INC?
CPRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of CPRX stock?
CPRX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 8 out of 10.
On which exchange is CPRX stock listed?
CPRX stock is listed on the Nasdaq exchange.
Can you provide the number of employees for CATALYST PHARMACEUTICALS INC?
CATALYST PHARMACEUTICALS INC (CPRX) currently has 181 employees.
When does CATALYST PHARMACEUTICALS INC (CPRX) report earnings?
CATALYST PHARMACEUTICALS INC (CPRX) will report earnings on 2026-02-24, after the market close.
CPRX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to CPRX. When comparing the yearly performance of all stocks, CPRX is one of the better performing stocks in the market, outperforming 79.87% of all stocks.
CPRX Fundamental Analysis
ChartMill assigns a fundamental rating of 8 / 10 to CPRX. Both the health and profitability get an excellent rating, making CPRX a very profitable company, without any liquidiy or solvency issues.
CPRX Financial Highlights
Over the last trailing twelve months CPRX reported a non-GAAP Earnings per Share(EPS) of 1.72. The EPS increased by 45.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 37.64% | ||
| ROA | 20.69% | ||
| ROE | 23.65% | ||
| Debt/Equity | 0 |
CPRX Forecast & Estimates
14 analysts have analysed CPRX and the average price target is 35.19 USD. This implies a price increase of 48.98% is expected in the next year compared to the current price of 23.62.
For the next year, analysts expect an EPS growth of 19.91% and a revenue growth 19.37% for CPRX